Anbio Biotechnology Class A Ordinary Shares (NNNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a cash flow conversion efficiency ratio of 0.093x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Million) by net assets ($17.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Anbio Biotechnology Class A Ordinary Sha (NNNN) liquidity interval to measure how many days the company can operate on defensive assets alone.
Anbio Biotechnology Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anbio Biotechnology Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haining China Leather Market Co Ltd
SHE:002344
|
-0.023x |
|
Quanta Storage
TWO:6188
|
-0.024x |
|
Manitou BF S.A.
PA:MTU
|
0.154x |
|
Admie Holding S.A
AT:ADMIE
|
0.048x |
|
Qt Group Oyj
HE:QTCOM
|
0.064x |
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
-0.002x |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
-0.055x |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
0.021x |
Annual Cash Flow Conversion Efficiency for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see NNNN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.16 Million | $-6.74 Million | -0.223x | -284.68% |
| 2024-12-31 | $17.19 Million | $2.08 Million | 0.121x | +99.61% |
| 2023-12-31 | $14.82 Million | $898.37K | 0.061x | -82.90% |
| 2022-12-31 | $12.55 Million | $4.45 Million | 0.355x | -78.50% |
| 2021-12-31 | $2.54 Million | $4.18 Million | 1.649x | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more